Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia
NCT04629443
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
17
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Leukaemia
Interventions
DRUG:
S 64315 (also referred as MIK665) and azacitidine
Sponsor
Institut de Recherches Internationales Servier
Collaborators
[object Object]